u/dose_diary_dana

the month-3 note is exactly that. i very nearly went up a dose to fix a stall that fixed itself.

I did, will pull that together for the next update, good idea

edit for the thread: several people asking what dose. not answering, and not because i am being coy — it is the one rule in every community here and it is the right rule.

the holiday season row is honestly the one I'm proudest of, expected it to be much worse

the comments on the log are what kept it going. accountability from strangers works and i did not expect it to.

hadn't separated those two things before, "the tracking was the project" is probably more accurate for me than "the weight loss was the project"

78 weeks of public logging and I've got about four months of maintenance-floor data now. weight's held within a kilo the whole time on a noticeably lower dose than what I used to titrate. still a bit nervous every time I step down further though. for anyone curious what "noticeably lower" means in actual numbers: titrated up to 2.4mg, currently holding steady at 1.0mg, that's 1.0 ÷ 2.4 = about 42% of peak dose maintaining the same weight.

Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.

my own log went from daily obsessive entries to barely-monthly ones around this exact point, and I remember it feeling like losing a hobby, not gaining freedom, at least at first.

a rejected claim is not the same as a denied authorization

78 weeks into my own public log and the pattern you're describing (nothing week 1-4, mild something week 5-8) is close to the median shape I've seen reported. Useful that you're logging it plainly instead of dramatizing it.

78 weeks of logging and this exact "went up, some of it was water, can't fully untangle it now" story is in my own data at least once. hard lesson, common one.

would love a log of the actual four-month step-down schedule if you're willing to share it, purely as "here's what one person did" reference, not asking for a recommendation

A peer-to-peer conversation puts the prescribing clinician in front of a reviewing clinician.

Agreed — and request the bulletin by number. They have to give it to you.

Why contemporaneous beats reconstructed, with the failure mode.

Memory smooths. Reconstructing a fortnight from recollection produces a series that is more regular, more consistent with your current beliefs, and quietly wrong in a direction that flatters the story you are already telling.

I found this out by reconstructing six weeks and later finding order receipts that contradicted my own entries. The log was not a little wrong; it was wrong in exactly the direction that made my narrative work. Write it down on the day, even the boring days, especially the boring days.

Apotheke pricing and pharmacy pricing elsewhere are different systems

Left up. Dates, consistent conditions and annotations, which is the standard here.

Did the clothes change before the number did for you too?

the middle is the part nobody posts and everybody lives in

Small correction, kindly meant: that is a range rather than a regain. Weight moves day to day in everybody.

Every claim I could trace in this board went back to about four papers. That was a sobering afternoon.

On cross-border prescriptions, since the assumption behind half these threads is wrong.

There are EU rules on the recognition of prescriptions issued in another member state, and they are conditional: the prescription has to meet requirements about its form and content, certain categories are excluded, and pharmacies retain discretion in practice.

The result is that "my prescription will be accepted anywhere in the EU" is not a safe assumption, and members here have discovered it at a counter in another country. If it matters for a trip, check before you travel with the pharmacy and with somebody qualified where you are. Nothing on this board is advice about that, and the rules are national in their application whatever the framework says.

Cosigning on quantity limits. They stop as many people as outright denials do and get discussed far less.

Added the Log flair and a date range to the title so it is findable later.

Pack sizes and presentations differ between member states, so a headline price is not comparable until it is normalised to a common quantity.

Which province?

Moved provinces and the coverage position changed completely. Same person, same history, different formulary.

Was this a denied authorization or a rejected claim?

Nobody has to post a starting weight, and comments demanding one get removed.

Stalled for 21 weeks and measured my waist out of stubbornness. It had moved. The scale had not.

That advice is jurisdiction-specific and this board spans several. Say where you are.

Agreed. The denial letter tells you which criterion failed, and answering that specific criterion is the entire job.

Agreed — authorisation is European, reimbursement is national, and almost every confused thread here misses that split.

The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.

the timeframe matters as much as the number

research-use-only labelling is not a customs category

a plateau is not a failure and it is not a personality

Slight disagreement: that is a month, not a plateau, and calling it one makes it heavier than it is.

Left up. Dates, consistent conditions and annotations, which is the standard here.

Left up. Dates, consistent conditions and annotations, which is the standard here.

pentadecapeptide, fifteen residues, and the sequence is public